Table 1 List of nanocarriers described in this review according to the targets related to autophagy

Autophagosome fusion with lysosomes

Chloroquine

Cisplatin

Hybrid dendritic–linear–dendritic block copolymers (HDLDBCs)

Cervical cancer and lung adenocarcinoma

[62]

Lysosomes

Lys-05

Lysosomotropic detergent (MSDH)

Isaminoquinoline nanoparticle

Pancreatic cancer

[64]

N-((2-hydroxy-3-trimethylammonium) propyl) chitosan chloride (HTCC)

Fe3O4 magnetic NPs

Gastric carcinoma

[75]

mTOR

AZD8055

Albumin nanoparticles

Uveal melanoma

[76]

Rapamycin

Albumin nanoparticles

Multiple myeloma

[82]

Rapamycin

Albumin nanoparticles

Breast cancer

[83]

Rapamycin

Albumin nanoparticles

Untreatable advanced nonhematologic malignancies

[84]

Rapamycin

Albumin nanoparticles

Non-hematologic malignancies

[85, 86]

Rapamycin

Albumin nanoparticles

Perivascular epithelioid cell tumors (PEComa) and patients with a malignancy with relevant genetic mutations or mTOR pathway activation

[87]

Rapamycin

Pazopanib

Albumin nanoparticles

Non-adipocytic soft tissue sarcomas

[88]

Rapamycin

Nivolumab

Albumin nanoparticles

Non-hematologic malignancies

[89]

Rapamycin

FOLFOX, Bevacizumab

Albumin nanoparticles

Metastatic colorectal cancer

[90]

Rapamycin

Temozolomide and irinotecan

Albumin nanoparticles

Recurrent or refractory solid tumors

[91]

Rapamycin

Gemcitabine

Albumin nanoparticles

Non-muscle invasive bladder cancer

[92]

Paclitaxel

Albumin nanoparticles

Metastatic breast cancer

[93]

Paclitaxel

Gemcitabine

Albumin nanoparticles

Pancreatic cancer

[94]

Paclitaxel

Carboplatin

Albumin nanoparticles

Non-small-cell lung cancer

[95]

Rapamycin

Albumin nanoparticles

Advanced solid tumors

[96]

Rapamycin

Albumin nanoparticles

Solid tumors

[97]

Everolimus

Albumin nanoparticles

Metastatic melanoma

[98]

Paclitaxel

Rapamycin

Albumin nanoparticles

Advanced solid tumors

[99]